Pharma 2026 Outlook (1/2): Maintain Market Perform
Eric Axon, CFA - Co-Head of High Yield, Head of Healthcare, CreditSights
Patrick Cunniff - Analyst, Healthcare, CreditSights
6 January 2026
Insights into CreditSights Pharma 2026 Outlook (1/2): Maintain Market Perform, including:
- Market Perform rating sustained despite revenue growth headwinds from patent losses: Consequently, pharma fundamentals remain healthy though M&A activity will drive modest leveraging trends ahead.
- Medicare price negotiations deliver 38-79% gross discounts on initial drug basket: IRA-mandated reductions take effect January 2026 with incremental impact on net pricing expectations.
- Patent expirations accelerate with $366 billion aggregate revenues at risk through 2030: Notable LOEs affect Keytruda, Eliquis, Vyndaqel requiring enhanced pipeline development and business diversification strategies.
- M&A capacity remains robust across investment-grade pharma limiting downgrade risks: Moreover, bolt-on and medium-sized transactions expected as companies address growth needs and exclusivity losses.
- Most Favored Nation pricing resolved through voluntary Medicaid reductions: Drugmaker agreements satisfy administration goals while limiting discounts to 3-11% revenue exposure business line.
Executive Summary
Credit fundamentals are expected to remain healthy despite operational headwinds from patent losses and pricing. Leverage may increase as M&A activity responds to these industry challenges in 2026.
Pharma sector anticipates 7.4% revenue growth through 2030 driven by innovative drug approvals. Consequently, growth distribution will vary significantly among companies based on product launches versus losses.
Patent expirations will accelerate materially affecting nearly all companies with notable exposure across portfolios. These losses create pressure on late-stage pipelines, commercial launches, and business development activities.
Bolt-on and medium-sized M&A transactions are anticipated as companies strengthen their late-stage pipelines.However, robust M&A capacity across the sector should limit potential downgrade risks ahead.
Moderate new issue volumes are expected with most companies refinancing their 2026 debt maturities. M&A financing will represent the primary variable affecting overall issuance volumes this year.
